[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:chronic-lymphocytic-leukemia:tp53-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Chronic Lymphocytic Leukemia","TP53 Gene",6,[8,16,23,29,35,41],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07566364","Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD",[12],"Phase 2","RECRUITING","2026-08-26T02:19:03.581490Z","2026-05-13T02:55:06.731598Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07342478","ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R\u002FR CLL\u002FSLL",[20],"Phase 3","2026-08-26T02:18:31.164304Z","2026-05-13T02:55:06.695894Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04169737","Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[12],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:28.287166Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT03128879","Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL",[12],"2026-08-03T03:15:35.967581Z","2026-04-29T02:57:57.177996Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT03824483","Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)",[12],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:27.422581Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT04329728","The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies",[45],"Phase 1\u002FPhase 2","2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.628795Z"]